J. Adam, F. Lešník
Genesis of vaccination against human papillomaviruses began with a successful start
of the first monovalent HPV 16 L1 VLP vaccine program. Before the introduction
of bivalent HPV 16 L1/18 VLP vaccine with an adjuvant of aluminum salts (Cervarix
®), the market got four-(quadri)-valent vaccine targeted at HPV types 6/11/16/18,
which are responsible for approximately 70% of cervical cancer and 90% of warts.
This vaccine is known as Gardasil®, Silgard, respectively. Finally, in 2014 the market
gets nine-valent Gardasil 9. The vaccine by its unique composition is targeted at
HPV types, which represent 90% of the proximate precursors of cervical cancer globally,
and 90% of invasive cervical cancers. 9vHPV vaccine offers a significantly wider
protection and, moreover, can be applied to boys and men. In light of this the new
vaccine marks another milestone in the immunoprophylaxis in clinical vaccinology.